Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Engage Grants Program

Dalhousie University

$25,000.00

The effect of iron chelation on the gut microbiome

FY 2016-17

Summary
Chelation Partners Inc. is developing a class of drugs that sequester iron, intended to enhance the activities ofantibiotics by preventing microbes from taking up iron. In early preclinical trials, Chelation Partners Inc.'s leaddrug proved to not adversely affect rat health when given orally. While this outcome is highly encouraging,whether the drug altered the animals' intestinal microbiome is unknown. Nor is it know whether the drugaffected the normal functions of the intestinal epithelium, though subclinically. It is possible that thecombination of changes in the microbiome with subclinical effects of iron chelation on epithelial cell biologyrenders the animal susceptible to a secondary challenge such as infection. The partners in this submission bringtogether the experience and capability to answer these questions. Dr. Stadnyk is an expert in intestinalepithelial pathophysiology, including extensive experience working with mouse models of induced intestinaldisease. In the first phase of the project Dr. Stadnyk will determine whether oral dosing mice with ChelationPartners Inc.'s lead drug changes the healthy animal's intestinal bacterial populations. This experiment will alsohelp establish a dosing of the drug to be used to determine whether chelating iron alters a mouse's susceptibilityto experimental chemical colitis. All the techniques and technologies to conduct the experiments are availableand active in Dr. Stadnyk's research network. Oral application of the drug is highly desirable but consideringthe growing awareness of the gut microbiome in human and animal health, it is critical to understand whetherthe drug alone (and therefore iron chelation as an adjuvant for antibiotics) has consequences on bacterialpopulations that possibly predispose the animals to illness.
Program
Engage Grants Program
Location
Nova Scotia, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
494787-2016
Name nom
Stadnyk, Andrew
Department département
Pediatrics
Organization id
79
Institution établissement
Dalhousie University
Province en
Nova Scotia
Province fr
Nouvelle-Écosse
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2016
Competition year année de concours
2016
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1551
Committee name en
Atlantic Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Atlantique
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5200
Research subject group en
Microbiology
Research subject group fr
Microbiologie
Research subject en
Microbiology
Research subject fr
Microbiologie
Partie
1
Nb partie
1
Application title
The effect of iron chelation on the gut microbiome
Keyword
NSERC
Application summary
Chelation Partners Inc. is developing a class of drugs that sequester iron, intended to enhance the activities ofantibiotics by preventing microbes from taking up iron. In early preclinical trials, Chelation Partners Inc.'s leaddrug proved to not adversely affect rat health when given orally. While this outcome is highly encouraging,whether the drug altered the animals' intestinal microbiome is unknown. Nor is it know whether the drugaffected the normal functions of the intestinal epithelium, though subclinically. It is possible that thecombination of changes in the microbiome with subclinical effects of iron chelation on epithelial cell biologyrenders the animal susceptible to a secondary challenge such as infection. The partners in this submission bringtogether the experience and capability to answer these questions. Dr. Stadnyk is an expert in intestinalepithelial pathophysiology, including extensive experience working with mouse models of induced intestinaldisease. In the first phase of the project Dr. Stadnyk will determine whether oral dosing mice with ChelationPartners Inc.'s lead drug changes the healthy animal's intestinal bacterial populations. This experiment will alsohelp establish a dosing of the drug to be used to determine whether chelating iron alters a mouse's susceptibilityto experimental chemical colitis. All the techniques and technologies to conduct the experiments are availableand active in Dr. Stadnyk's research network. Oral application of the drug is highly desirable but consideringthe growing awareness of the gut microbiome in human and animal health, it is critical to understand whetherthe drug alone (and therefore iron chelation as an adjuvant for antibiotics) has consequences on bacterialpopulations that possibly predispose the animals to illness.